Table 2 Changes from baseline in ADAS-cog for on-treatment population
From: Effect of TTP488 in patients with mild to moderate Alzheimer’s disease
3 months | 6 months | 9 months | 12 months | 15 months | 18 months | |
|---|---|---|---|---|---|---|
5 mg/day | 1.43 ± 0.50 | 2.52 ±0.56 | 3.02 ± 0.62 | 5.14 ± 0.75 | 7.18 ± 0.81 | 8.96 ± 1.07 |
(n = 126) | (n = 118) | (n = 106) | (n = 95) | (n = 83) | (n = 63) | |
Placebo | 1.58 ± 0.44 | 3.16 ± 0.54 | 3.99 ± 0.68 | 6.26 ± 0.69 | 8.74 ± 0.91 | 11.63 ± 1.15 |
(n = 127) | (n = 114) | (n = 109) | (n = 101) | (n = 86) | (n = 59) | |
p = 0.03 |